Document is current
Any future updates will be listed below
-
Authors
Montomoli, Marco https://orcid.org/0000-0003-1412-6352
Solano Rivera, Camila
Rico, Miguel Gonzalez
De la Espriella Juan, Rafael
Nuñez Marín, Gonzalo
Puchades Montesa, Maria Jesús
Gorriz Teruel, Jose Luis
-
Funding
Funding for this research was provided by:
AstraZeneca España
- License Information
-
More Information
Article History
Received: 8 July 2024
Accepted: 26 November 2024
First Online: 19 December 2024
Declarations
:
: This study was approved and authorized by both the Spanish Agency of Drugs and Health Products (AEMPS) and the Hospital Clínico Universitario de Valencia Ethical Committee (CEIM) according to the World Medical Association Declaration of Helsinki. (CEIM FILE: 148/23, CODE: DAPA-DP, EUDRACT no.: 2023-505571-78-00). The investigated drug has received approval from the European Medicines Agency (EMA) and has been authorized for commercialization in Spain. Informed consent will be obtained from the participants according to the model approved by the CEIM for ethics approval and participation.
: As the lead author, I provide my explicit consent for the publication of the manuscript and take responsibility for ensuring that all the coauthors equally endorse its publication.
: Not applicable.
